<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">26870914</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>12</Month>
            <Day>26</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>02</Month>
            <Day>03</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1464-5491</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>33</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>10</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Diabetic medicine : a journal of the British Diabetic Association</Title>
                <ISOAbbreviation>Diabet. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Long-term outcome of insulin pump therapy: reduction of hypoglycaemia and impact on glycaemic control.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1422-6</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/dme.13094</ELocationID>
            <Abstract>
                <AbstractText Label="AIMS">To determine the long-term outcome of continuous subcutaneous insulin infusion (CSII) in Type 1 diabetes according to Catalan National Health Service indications.</AbstractText>
                <AbstractText Label="METHODS">Retrospective observational study including 178 patients with Type 1 diabetes who started CSII treatment in our centre (2003-2008). All patients were followed in our CSII programme for outpatients for at least 5 years. Data on annual HbA1c levels were collected, and the main indication for starting CSII was analysed.</AbstractText>
                <AbstractText Label="RESULTS">Twenty-seven of 178 patients were excluded because of loss to follow-up or withdrawal from CSII, thus 151 patients (aged 37.4 ± 10.5 years, 64% women) were analysed. The main indications for starting CSII were suboptimal metabolic control (60.9%), severe hypoglycaemia/hypoglycaemia unawareness (25.5%) and others (13.6%). HbA1c was 64 ± 13 mmol/mol (8.0 ± 1.2%) at the start of CSII and 62 ± 13 mmol/mol (7.8 ± 1.2%) after 5 years in the total cohort (P = 0.1). The severe hypoglycaemia rates were 0.66 ± 1.61 and 0.17 ± 0.42 episodes/patient/year (P &lt; 0.001). In patients with suboptimal metabolic control, HbA1c decreased from 68 ± 12 mmol/mol (8.4 ± 1.1%) to 64 ± 14 mmol/mol (8.0 ± 1.3%) (P = 0.016), with 37.4% of those in this group having an HbA1c ≤ 58 mmol/mol (7.5%) after 5 years. In patients starting CSII due to severe hypoglycaemia the problem was considered resolved in 93%, and in 64% of those starting CSII because of suboptimal glycaemic control, HbA1c improved significantly.</AbstractText>
                <AbstractText Label="CONCLUSIONS">CSII therapy achieves and maintains its efficacy mainly in terms of reducing severe hypoglycaemia. In the whole group of patients, the reduction in HbA1c is transient and disappears after 5 years.</AbstractText>
                <CopyrightInformation>© 2016 Diabetes UK.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Quirós</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Diabetes Unit, Endocrinology, Department, Hospital Clínic i Universitari, Barcelona, Spain. cmquiros@clinic.ub.es.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Giménez</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Diabetes Unit, Endocrinology, Department, Hospital Clínic i Universitari, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ríos</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Diabetes Unit, Endocrinology, Department, Hospital Clínic i Universitari, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Careaga</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Diabetes Unit, Endocrinology, Department, Hospital Clínic i Universitari, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Roca</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Diabetes Unit, Endocrinology, Department, Hospital Clínic i Universitari, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vidal</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Diabetes Unit, Endocrinology, Department, Hospital Clínic i Universitari, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Conget</LastName>
                    <ForeName>I</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>Diabetes Unit, Endocrinology, Department, Hospital Clínic i Universitari, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D064888">Observational Study</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>04</Month>
                <Day>28</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Diabet Med</MedlineTA>
            <NlmUniqueID>8500858</NlmUniqueID>
            <ISSNLinking>0742-3071</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003922" MajorTopicYN="N">Diabetes Mellitus, Type 1</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007003" MajorTopicYN="N">Hypoglycemia</DescriptorName>
                <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007332" MajorTopicYN="Y">Insulin Infusion Systems</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2015</Year>
                <Month>04</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2015</Year>
                <Month>12</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>02</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>2</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>2</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26870914</ArticleId>
            <ArticleId IdType="doi">10.1111/dme.13094</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>